What is the real-world experience of R/R AML treatment with venetoclax + HMAs?

During the EHA2021 Virtual Congress, the AML Hub spoke with Courtney DiNardo, MD Anderson, Houston, US. We asked, What is the real-world experience of relapsed/refractory AML treatment with venetoclax and hypomethylating agents (HMAs)?

In this video, DiNardo explains how the response rate of this regimen compares to other salvage chemotherapy options. She highlights that patients in the relapse setting have a higher chance of responding to this HMA regimen, including patients with diploid cytogenetics or MPN1, IDH1, and IDH2 mutations.